Nature communications
Intrathecal CRISPR-edited allogeneic IL-13Rα2 CAR T Cells for recurrent high-grade Glioma: preclinical characterization and phase I trial.
Xuetao Li, Xiaoyun Shang, Jiangang Liu, Yang Zhang, Xian Jia, Huabing Li, Yihan Wang, Jianen Gao, Xu Ma, Xuewen Zhang, Xiaoci Rong, Wenjuan Gan, Yu Zhang, Jie Chen, Lin Wang
Published: 202610.1038/s41467-025-68112-6
Abstract
Patients with recurrent high-grade glioblastoma have a median survival of 6-8 months, with limited therapeutic options. In recent years, interest has grown in applying chimeric antigen receptor T (CAR-T) cells to solid cancers, including advanced gli…
Preview only. Read the full abstract at the source